Financials
Financial year 2025
Dr. Jeroen Mertens, Nucleaire Geneeskunde from Gent, company number BE0704757557, closed financial year 2025 with a result of € 455,424 after tax. For that financial year Dr. Jeroen Mertens, Nucleaire Geneeskunde recorded a gross margin of € 597,295 and equity of € 225,299. Compared with financial year 2024, the result moved from € 450,831 to € 455,424. Profitable, and profit is growing. The company holds a healthy buffer. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 10, 2026.
€ 225,299
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 455,424
▲ 1% vs 2024
Profit after tax over the fiscal year.
€ 704,602
▲ 37% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 456,000 paid out
100 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
€ 8,459
▼ 22% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 29,444
▲ 16% vs 2024
Supplier invoices still open on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 431,801 | € 477,906 | € 613,304 | € 597,295 | ▼ 3% |
| Profit after taxes | € 319,857 | € 357,282 | € 450,831 | € 455,424 | ▲ 1% |
| Equity | € 303,934 | € 304,216 | € 225,875 | € 225,299 | |
| Total debts | € 384,599 | € 436,213 | € 626,819 | € 726,364 | ▲ 16% |
| Cash | € 352,482 | € 343,638 | € 512,651 | € 704,602 | ▲ 37% |
| Retained profit | € 285,334 | € 285,616 | € 207,275 | € 206,699 | |
| Dividend | € 321,000 | € 357,000 | € 529,172 | € 456,000 | ▼ 14% |
| Bank debt | € 33,404 | € 33,849 | € 32 | € 0 | ▼ 100% |
| Balance sheet total | € 688,533 | € 740,428 | € 852,694 | € 951,663 | ▲ 12% |
Key figures of Dr. Jeroen Mertens, Nucleaire Geneeskunde, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Dr. Jeroen Mertens, Nucleaire Geneeskunde?
What happened at Dr. Jeroen Mertens, Nucleaire Geneeskunde in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 455,424 (▲ 1% vs 2024). Source: NBB ↗
- New establishment in Merelbeke-Melle. KBO
- Start of the company according to the CBE. KBO
- Jeroen Mertens became a director. NBB
In short
From € 319,857 profit in 2022 to € 455,424 profit in 2025.
Paid € 500,999 in corporate taxes since 2022.
Best year ever: 2025, with € 455,424 profit.
Paid out € 1.7 million in dividends to the owners in total.
Management
Behind Dr. Jeroen Mertens, Nucleaire Geneeskunde is Jeroen Mertens.
Directors
According to the 2025 annual accounts
Jeroen Mertens
Director
since 2018
Establishments
Establishment units
Physical locations of this company
Lange Violettestraat 211
9000 Gent
Hof Resselaar 25
9820 Merelbeke-Melle
Active since 19 September 2018
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0704.757.557
- VAT number
- BE 0704.757.557
- Registered office
- Lange Violettestraat 211, 9000 Gent
- Names & denominations
- Dr. Jeroen Mertens, Nucleaire Geneeskunde
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 19 September 2018
- Peppol
- Active · Active since 5 Nov 2025
- Activities · NACE
Activiteiten van medisch specialisten